Actively Recruiting
Effects of Combined 40 Hz Audio-visual Stimulation and Cognitive Games on Alzheimer's Disease
Led by Istanbul Medipol University Hospital · Updated on 2024-09-19
30
Participants Needed
1
Research Sites
134 weeks
Total Duration
On this page
Sponsors
I
Istanbul Medipol University Hospital
Lead Sponsor
T
The Scientific and Technological Research Council of Turkey
Collaborating Sponsor
AI-Summary
What this Trial Is About
In addition to ongoing drug treatments for Alzheimer Disease (AD), protective approaches that can halt the progression of the disease are of particular importance. This project aims to develop a digital application that can monitor cognitive impairment, using EEG findings proven effective at the clinical level in Alzheimer and various types of dementia, including sensory entrainment and digital cognitive games. To this end, a collaboration between Istanbul Medipol University and Güven Future Health Technologies Inc. will develop a device featuring audio-visual sensory entrainment and digital cognitive games. This device will be made available to Alzheimer patients, and the differences between patients who use the application for three months, patients who do not use the application, and healthy controls will be evaluated through neurological examinations, neuropsychological tests, and EEG recordings indicating cognitive functions by the neurologist, project coordinator, and bursars. Monthly assessments, including EEG recordings, will also continue at home, and an application will be created to evaluate changes in cognitive functions through EEG data. By the end of the project, an application that includes sensory entrainment and digital cognitive games, proven effective at the clinical level using EEG findings for Alzheimer dementia patients, will be developed. Additionally, a health kit capable of temporal monitoring of cognitive function changes through EEG data will have been developed.
CONDITIONS
Official Title
Effects of Combined 40 Hz Audio-visual Stimulation and Cognitive Games on Alzheimer's Disease
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosed with Alzheimer's disease according to DSM-IV and NINCDS-ADRDA criteria
- Impaired activities of daily living
- Clinical Dementia Rating (CDR) score between 1 and 2 and Standardized Mini-Mental State (SMMT) score between 15 and 26
- Stable use of psychoactive medications, including acetylcholinesterase inhibitors or other cognitive enhancers
- Age between 60 and 86 years with at least 5 years of education
- Healthy older adults aged 60 to 86 without neurological abnormalities or cognitive impairment (MMSE above 25)
- No diagnosis of neurological or psychiatric diseases and not using related medications
You will not qualify if you...
- Diagnosis of frontotemporal dementia, vascular dementia, Lewy body dementia, or other dementia types
- Presence of Parkinsonism, clinical depression, other mental disorders, epilepsy, drug or alcohol addiction, or traumatic brain injury
- Healthy older adults with any clinical signs of cognitive impairment including mild cognitive impairment, Alzheimer's disease, Parkinson's disease, Lewy body dementia, or frontotemporal dementia
- Use of medications affecting cognitive functions
- History of epilepsy, alcohol or drug addiction, or traumatic brain injury
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Istanbul Medipol University
Istanbul, Beykoz, Turkey (Türkiye), 34810
Actively Recruiting
Research Team
B
Bahar Güntekin, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here